全球猪疫苗市场规模（按适应症、技术、地区和预测）

猪疫苗市场规模及预测

2024 年猪疫苗市场规模价值 21.9 亿美元，预计到 2032 年将达到 38.3 亿美元，2026 年至 2032 年的复合年增长率为 7.27%。

推动全球猪隻疫苗市场成长的主要因素是猪肉消费量的增加和猪病的流行。此外，世界各国政府都在增加对动物保健领域的支出。全球猪疫苗市场报告对预测期内的市场进行了总体评估。报告分析了各个细分市场以及在市场中发挥重要作用的趋势和因素。

定义全球猪疫苗市场

疫苗是预防动物和人类疾病最重要的工具。疫苗接种在动物用药品中被认为是一项福音，可以预防许多地方性疾病的传播并保障动物福利。猪疫苗在临床上用于改善猪的健康状况，并透过保护猪免受病毒、细菌和其他病原体的侵害来预防致命疾病。

这些疾病包括猪繁殖与呼吸道病毒（PRRSV）、猪流感和猪环状病毒相关疾病（PCVAD）。它还能提高保护猪免受致命病毒侵害的整体效率，并增加供人类食用的优质肉类的产量。在北美和欧洲，霍乱和口蹄疫等多种疾病已透过使用这些疫苗而基本被消灭。

全球猪隻疫苗市场概况

猪肉消费量的增加是全球猪隻疫苗市场的主要驱动力。预计消费量的增加将增加保护猪群免受任何可能影响猪隻并对人类构成威胁的疾病的需求。这预计将推动对用于预防各种猪病的猪疫苗的需求。

由于全球猪流感、猪隻流行性腹泻（PED）和猪隻繁殖与呼吸症候群（PRRS）病例不断增加，仔猪早期免疫接种率也有所提高。其他重要推动因素包括加强对猪病的宣传，以及政府增加对兽医的资助。

技术进步和研发投入的不断扩大预计将带来新的商机，从而推动全球猪隻疫苗市场的成长。联合疫苗的生产提供了良好的成长机会。此外，DNA疫苗还能帮助农民在农场生产无病猪。因此，市场拥有充足的成长机会。然而，疫苗的维护、运输和储存成本高昂等一些阻碍因素预计将对猪疫苗产业的成长产生不利影响。

目录

第一章全球猪疫苗市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球猪疫苗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型

第五章全球猪疫苗市场（按适应症）

• 介绍
• 猪流感
• 腹泻
• 关节炎
• 猪繁殖与呼吸综合症
• 猪环状病毒相关疾病
• 其他的

6. 全球猪疫苗市场（依技术）

• 介绍
• 灭活疫苗
• 减毒活病毒疫苗
• 重组疫苗
• DNA疫苗
• 其他的

7. 全球猪疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 中东和非洲
  • 南美洲

第八章全球猪疫苗市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• Merial
• Zoetis Inc.
• Intervet Inc.
• Vetoquinol
• Bayer AG
• IDT Biologika GmbH
• HIPRA
• Ceva Sante Animale
• Elanco
• Arko Laboratories Ltd

第十章 附录

• 相关调查

Porcine Vaccine Market Size And Forecast

Porcine Vaccine Market size was valued at USD 2.19 Billion in 2024 and is projected to reach USD 3.83 Billion by 2032, growing at a CAGR of 7.27% from 2026 to 2032.

Some of the key contributing factors propelling the growth of the Global Porcine Vaccine Market are an increase in pork consumption and a rise in the prevalence of swine diseases. Also, governments across the globe are spending higher in the field of animal health care. The Global Porcine Vaccine Market report provides a holistic evaluation of the market for the forecast period. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.

Global Porcine Vaccine Market Definition

Vaccines are the most important disease prevention tools for both animals and humans. Vaccination is regarded as a boon in veterinary pharmaceuticals for preserving animal welfare by avoiding the spread of many endemic diseases. Porcine vaccines are used clinically to improve swine health and protect them from deadly diseases by guarding them against viruses, bacteria, and other pathogens.

Such diseases include porcine reproductive and respiratory virus (PRRSV), swine influenza, and porcine circovirus-associated disease (PCVAD) among others. It also increases the yield of high-quality meat for human consumption while improving overall efficiency in protecting pigs from deadly viruses. In North America and Europe, many diseases like cholera, foot & mouth disease have been significantly eliminated by using these vaccines.

Global Porcine Vaccine Market Overview

The increase in pork consumption is an important driver for the Global Porcine Vaccine Market. This increase in consumption is expected to result in a greater need to keep the swine population free of any disease that could affect them and pose a threat to humans. Thus the demand for swine vaccines that guards against various porcine diseases is expected to rise.

Also, higher instances of swine flu, porcine epidemic diarrhea (PED), and porcine reproductive and respiratory syndrome (PRRS) in farms worldwide have led to an increase in early vaccination of piglets. Other important drivers are the increasing number of awareness programs about porcine diseases and increased government funding for animal health care.

Technological advancements and growing research and development are expected to provide new profitable opportunities leading to the growth of the Global Porcine Vaccine Market. Combined vaccine production gives a good opportunity for growth. Also, DNA vaccines allow agriculture farmers to produce disease-free swine on their farms. Thus, there are ample growth opportunities for the market. However, there are some restraints like the high cost of maintaining, transportation, and storage of vaccines that are expected to adversely impact the growth of the Porcine Vaccine industry.

Global Porcine Vaccine Market Segmentation Analysis

The Global Porcine Vaccine Market is segmented on the basis of Disease Indication, Technology, And Geography.

Porcine Vaccine Market, By Disease Indication

• Swine Influenza
• Diarrhea
• Arthritis
• Porcine Reproductive and Respiratory Syndrome
• Porcine Circovirus Associated Disease
• Others

Based on Disease Indication, The market is segmented into Swine Influenza, Diarrhea, Arthritis, Porcine Reproductive and Respiratory Syndrome, Porcine Circovirus Associated Disease, and Others. Diarrhea and swine influenza dominate the Global Porcine Vaccine Market owing to factors like changes in climate including global warming and overfeeding of protein diet among others.

Porcine Vaccine Market, By Technology

• Inactivated vaccines
• Live attenuated vaccines
• Recombinant vaccines
• DNA vaccines
• Others

Based on Technology, The market is segmented into Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines, DNA vaccines, and Others. Inactivated vaccines are leading the market. DNA vaccines are gaining popularity in veterinary hospitals as they have several advantages over live attenuated vaccines and inactivated vaccines.

Porcine Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Porcine Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America leads the Global Porcine Vaccine Market by geography due to the rise in pork consumption, increasing instances of various swine diseases, and higher per-capita animal healthcare expenditure in the United States. The Asia Pacific region will have good growth due to increasing awareness about porcine health, and growing advancements in the field of biotechnology.

Key Players

The "Global Porcine Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bayer AG, Hipra, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A, Zoetis Inc., Arko Laboratories Ltd, and Vetoquinol. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• On August 5, 2021 Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-based biopharmaceutical company that specializes in novel detection technology to unlock high-volume, uncontrolled traditional therapies with specific therapies. The Vividion platform is capable of producing a wide range of therapeutic approaches to small molecules in all directions, with an initial focus on oncology and immunology. Vividion's leading programs include a wide range of oncology specification and immunology guidelines, with ongoing efforts to counteract NRF2 antagonism for the possible treatment of NRF2 cancer, and NRF2 activists for various inflammatory diseases such as acute intestinal disease - among other treatment programs.
• On February 18, 2021 Philippe Mauguin, INRAE chief executive officer and Drs. Marc Prikazsky, Chairman and CEO of Ceva Sante Animale (Ceva), signed a first-round agreement aimed at consolidating their animal health partnerships. This signature comes in the context of Covid-19 disease and the outbreak of bird flu in France. It affirms the shared goal of working together for the "One Health", global health concept at animal crossroads, human and environmental health and, in particular, to prevent infectious diseases from the environment and to improve animal welfare.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PORCINE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PORCINE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model

5 GLOBAL PORCINE VACCINE MARKET, BY DISEASE INDICATION

• 5.1 Introduction
• 5.2 Swine Influenza
• 5.3 Diarrhea
• 5.4 Arthritis
• 5.5 Porcine Reproductive and Respiratory Syndrome
• 5.6 Porcine Circovirus Associated Disease
• 5.7 Others

6 GLOBAL PORCINE VACCINE MARKET, BY TECHNOLOGY

• 6.1 Introduction
• 6.2 Inactivated vaccines
• 6.3 Live attenuated vaccines
• 6.4 Recombinant vaccines
• 6.5 DNA vaccines
• 6.6 Others

7 GLOBAL PORCINE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Middle East and Africa
  • 7.5.2 South America

8 GLOBAL PORCINE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Merial
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Zoetis Inc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Intervet Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Vetoquinol
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Bayer AG
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 IDT Biologika GmbH
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 HIPRA
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Ceva Sante Animale
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Elanco
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Arko Laboratories Ltd
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 APPENDIX

• 10.1 Related Research